A Biotech Company's Aggressive Move Backfires
96722
The suspension of Chiron's flu vaccine has not only cost it three-quarters in expected profits, but also some credibility.
45047
By Sabine Vollmer, The News & Observer, Raleigh, N.C.  Feb. 13--Cornerstone BioPharma is trying to bounce back after layoffs cut the Cary company's work force in half.
435276
The troubled pharmaceutical company begins to show signs of life.
174211
A drug manufacturer has been found to infringe patents licensed by the maker of a rival drug.
65620
Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
480137
The German pharmaceutical giant Bayer is no stranger to health and safety scares. Three years ago, it had to pull its cholesterol-lowering drug Baycol from the market and
524852
The biopharma's outlook is cloudy due to stiffer competition in biomanufacturing.
698753
MedImmune Inc.&#39;s cancellation of trials for an arthritis and psoriasis treatment sent the company&#39;s stock lower Monday and helped drag down the entire biotechnology sector.
527411
Competition makes for a dreary outlook for the company.
565353
If Biogen Idec Inc. is sold to a pharmaceuticals giant, as many biotech industry observers expect, it could spell the loss of yet another major corporate headquarters in Massachusetts, a blow to the state's prestige.
238313
A new study shows raises questions about the straying of plants altered through biotechnology and that could hurt the efforts of two companies to win approval for the first bioengineered grass.
82904
SHANGHAI -- Looking at the facts, the past year seems to have been disastrous for Worldbest Pharmaceutical.  First, there were reports of accounting irregularities and exaggerated profit. Half the managers were fired. Then, in the summer, six people died and at least 80 fell ill after receiving an antibiotic injection manufactured by a subsidiary. Most recently, the company warned investors that it was likely to report its third consecutive year of losses....
758482
Biopure Corp. , the Cambridge company trying to develop an artificial substitute for human blood, was battered in the stock market yesterday after a federal advisory council recommended against its effort to test the product on more than 1,000 trauma patients.
100064
Research and development costs drag down the drug developer's bottom line.
156850
Fifteen months ago, Genzyme Corp. and Transkaryotic Therapies Inc. of Cambridge decided to kiss and make up. It didn't last.
748007
The company is fumbling in its attempts to move to a new business model.
394781
CV Therapeutics out-licenses one of its technologies.